Cost-effectiveness analysis for clinicians

BMC Medicine

Commentary

Suzanne R Hill¹ 

[1] World Health Organization, 20 Ave Appia, Geneva 27, Switzerland;

关键词: Bronchiolitis;    Health Technology Assessment;    Incremental Cost Effectiveness Ratio;    Quality Adjusted Life Year;    Quality Adjusted Life;   

DOI  :  10.1186/1741-7015-10-10

 received in 2011-10-12, accepted in 2012-02-01,  发布年份 2012

来源: Springer

【 摘 要 】

In a climate of economic uncertainty, cost effectiveness analysis is a potentially important tool for making choices about health care interventions. Methods for such analyses are well established, but the results need to be interpreted carefully and are subject to bias. Making decisions based on results of cost-effectiveness analyses can involve setting thresholds, but for individual patients, there needs to be disaggregation of benefits and harms included in a quality adjusted life year to ensure appropriate consideration of benefits and harms as well as personal preferences and circumstances.

【 授权许可】

CC BY   
© Hill; licensee BioMed Central Ltd. 2012